SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom Genna who wrote (7)7/7/1996 5:14:00 PM
From: John Binford, Jr.   of 1754
 
Visx is being punished for Summit's poor performance. Earnings are to be released July 22 for Visx. This should help propel the stock back up. Visx is the laser of choice, and all of Summit's whining won't change that.

The WSJ article was reporting about Summit's complaint to the FDA that Visx is advertising its laser as treating astigmatism and high myopia. Logan was quoted as saying that Visx had done nothing wrong and had followed FDA guidelines. The complaint came because FDA guidelines recently allowed doctors to use the lasers for off-label uses. Therefore, Visx started shipping its key cards which allowed any type of procedure including astigmatic and high myopia.

I think at the current price Visx is a pretty good buy. After all PRK does work and works well.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News